英文原题:PD-1 antibody-bound progenitor-exhausted CD8(+) T cells in lymph nodes boost PD-1-blockade anti-tumor immunity in gastrointestinal cancer.
表达TCF1和PD-1的祖细胞耗竭T细胞(Tpex)对于免疫检查点抑制剂(ICIs)与治疗性抗PD-1抗体(aPD-1)的治疗效果至关重要,但ICI结合的Tpex的动态变化尚未完全清楚。
表达TCF1和PD-1的祖细胞耗竭T细胞(Tpex)对于免疫检查点抑制剂(ICIs)与治疗性抗PD-1抗体(aPD-1)的治疗效果至关重要,但ICI结合的Tpex的动态变化尚未完全清楚。在本研究中,我们利用单细胞水平的联合测序分析详细研究了ICI结合的T细胞。通过分析接受或未接受ICI治疗的胃肠道癌症患者的样本,我们发现Tpex在近端淋巴结(LNs)中富集,并在ICI治疗后以高速率增殖。重要的是,LNs中aPD-1高结合的Tpex与肿瘤内耗竭CD8+ T细胞(Tex)共享T细胞受体克隆型,提示它们在ICI治疗后迁移至肿瘤部位。因此,本研究为ICIs如何通过作用于LNs中的Tpex增强抗肿瘤免疫提供了新的见解,加深了我们对ICI治疗细胞机制的理解。
While progenitor-exhausted T cells (Tpex) expressing TCF1 and PD-1 are crucial for the therapeutic effect of immune checkpoint inhibitors (ICIs) with therapeutic anti-PD-1 antibodies (aPD-1), the dynamics of ICI-bound Tpex are not fully understood. In this study, we investigate ICI-bound T cells in detail using combined sequencing analysis at the single-cell level. By analyzing samples from gastrointestinal cancer patients with or without ICI treatment, we find that Tpex are enriched in proximal lymph nodes (LNs) and proliferate at a high rate after ICI treatment. Importantly, aPD-1 high-bound Tpex in LNs share T-cell receptor clonotypes with intratumoral exhausted CD8 + T cells (Tex), suggesting their migration to tumor sites after ICI treatment. This study thus provides new insights into how ICIs enhance anti-tumor immunity by acting on Tpex in LNs, deepening our understanding of the cellular mechanisms underlying ICI therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。